Published April 30, 2020 | Version v1
Journal article Open

FAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19

Authors/Creators

  • 1. Professor Dr. Postgraduate Program in Family Health (RENASF) - Federal University of Rio Grande do Norte
  • 2. Student. Federal University of Rio Grande do Norte. Brazil
  • 3. Professor MsC. Federal University of Rio Grande do Norte. Brazil
  • 4. Professor Dr. Federal University of Rio Grande do Norte. Brazil
  • 5. Professor MSc. Federal Institute of Education, Science and Technology of Tocantins
  • 6. Professor Dra Estácio University. Brazil

Description

Favipiravir is a drug developed for use against influenza and has been used successfully in other infectious conditions. After being internalized in the cell, the substance is phosphoribosylated acting on the RNA polymerase, and thus inhibiting replication and RNA viruses. Thus, the present study aimed to discuss the potential use of favipiravir in coronovavirus infections. There have been few studies involving favipiravir in COVID 19, however there is a report of recovery in more than 70% of patients diagnosed with pneumonia. However, new studies need to be carried out, mainly randomized clinical trials, so that the potential use of favipiravir in coronaviruses is adequately grounded

Files

02_IJRG20_B04_3242.pdf

Files (325.8 kB)

Name Size Download all
md5:a054f9298a302eab3d5a56fdbe9de933
325.8 kB Preview Download